Literature DB >> 10712989

Acute exacerbation of COPD: factors associated with poor treatment outcome.

N A Dewan1, S Rafique, B Kanwar, H Satpathy, K Ryschon, G S Tillotson, M S Niederman.   

Abstract

OBJECTIVES: To determine the effect of age, severity of lung disease, severity and frequency of exacerbation, steroid use, choice of an antibiotic, and the presence of comorbidity on the outcome of treatment for an acute exacerbation of COPD.
DESIGN: A retrospective chart analysis over 24 months.
SETTING: A university Veterans Affairs medical center. PATIENTS: Outpatients with COPD who were treated with an antibiotic over a period of 24 months for an acute exacerbation of COPD.
METHODS: Severity of an acute exacerbation of COPD was defined using the criteria of Anthonisen et al: increased dyspnea, increased sputum volume, and increased sputum purulence. Severity of lung disease was stratified based on FEV(1) percent predicted using American Thoracic Society guidelines (stage I, FEV(1) > or = 50%; stage II, FEV(1) 35 to 49%; stage III, FEV(1) < 35%). Treatment outcome was judged successful when the patient had no return visit in 4 weeks for a respiratory problem. Failure was defined as a return visit for persistent respiratory symptoms that required a change of an antibiotic in < 4 weeks.
RESULTS: One-hundred seven patients with COPD (mean age +/- SD, 66.9 +/- 9.5 years) experienced 232 exacerbations over 24 months. First-line antibiotics (trimethoprim-sulfamethoxazole, ampicillin/amoxicillin, and erythromycin) were used to treat 78% of all exacerbations. Treatment failure was noted in 12.1% of first exacerbations and 14. 7% of all exacerbations, with more than half the failures requiring hospitalization. Host factors that were independently associated with treatment failure included the following: FEV(1) < 35% (46.4% vs 22.4%; p = 0.047), use of home oxygen (60.7% vs 15.6%; p < 0. 0001), frequency of exacerbation (3.8 +/- 2.0 vs 1.6 +/- 0.91; p < 0. 001), history of previous pneumonia (64.3% vs 35.1 p < 0.007), history of sinusitis (28.6% vs 8.8%; p < 0.009) and use of maintenance steroids (32.1% vs 15.2% p = 0.052). Using stepwise logistic regression analysis to identify the top independent variables, the use of home oxygen (p = 0.0002) and frequency of exacerbation (p < 0.0001) correctly classified failures in 83.3% of the patients. Surprisingly, age, the choice of an antibiotic, and the presence of any one or more comorbidity did not affect the treatment outcome.
CONCLUSION: The results of our study suggest that patient host factors and not antibiotic choice may determine treatment outcome. Prospective studies in appropriately stratified patients are needed to validate these findings.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10712989     DOI: 10.1378/chest.117.3.662

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  39 in total

Review 1.  Assessment of progression of COPD: report of a workshop held in Leuven, 11-12 March 2004.

Authors:  M Decramer; R Gosselink; M Rutten-Van Mölken; J Buffels; O Van Schayck; P-A Gevenois; R Pellegrino; E Derom; W De Backer
Journal:  Thorax       Date:  2005-04       Impact factor: 9.139

2.  Intermediate care--Hospital-at-Home in chronic obstructive pulmonary disease: British Thoracic Society guideline.

Authors: 
Journal:  Thorax       Date:  2006-11-07       Impact factor: 9.139

3.  One-year and long-term mortality in patients hospitalized for chronic obstructive pulmonary disease.

Authors:  María-Teresa García-Sanz; Juan-Carlos Cánive-Gómez; Laura Senín-Rial; Jorge Aboal-Viñas; Alejandra Barreiro-García; Eva López-Val; Francisco-Javier González-Barcala
Journal:  J Thorac Dis       Date:  2017-03       Impact factor: 2.895

Review 4.  Macrolides: from in vitro anti-inflammatory and immunomodulatory properties to clinical practice in respiratory diseases.

Authors:  P Zarogoulidis; N Papanas; I Kioumis; E Chatzaki; E Maltezos; K Zarogoulidis
Journal:  Eur J Clin Pharmacol       Date:  2011-11-22       Impact factor: 2.953

5.  Determinants of spirometry use and accuracy of COPD diagnosis in primary care.

Authors:  Min J Joo; David H Au; Marian L Fitzgibbon; Joanne McKell; Todd A Lee
Journal:  J Gen Intern Med       Date:  2011-06-29       Impact factor: 5.128

6.  Healthcare costs with tiotropium plus usual care versus usual care alone following 1 year of treatment in patients with chronic obstructive pulmonary disorder (COPD).

Authors:  Mitchell Friedman; Shailendra S Menjoge; Susan F Anton; Steven Kesten
Journal:  Pharmacoeconomics       Date:  2004       Impact factor: 4.981

7.  Co-morbidity and acute decompensations of COPD requiring non-invasive positive-pressure ventilation.

Authors:  Raffaele Scala; Sandra Bartolucci; Mario Naldi; Marcello Rossi; Mark W Elliott
Journal:  Intensive Care Med       Date:  2004-07-17       Impact factor: 17.440

8.  Antimicrobials in acute exacerbations of chronic obstructive pulmonary disease - An analysis of the time to next exacerbation before and after the implementation of standing orders.

Authors:  Rob D Goddard; Shelly A McNeil; Kathryn L Slayter; R Andrew McIvor
Journal:  Can J Infect Dis       Date:  2003-09

9.  Prior cardiovascular disease increases long-term mortality in COPD patients with pneumonia.

Authors:  Oriol Sibila; Eric M Mortensen; Antonio Anzueto; Elena Laserna; Marcos I Restrepo
Journal:  Eur Respir J       Date:  2013-04-18       Impact factor: 16.671

10.  Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease.

Authors:  G C Donaldson; T A R Seemungal; A Bhowmik; J A Wedzicha
Journal:  Thorax       Date:  2002-10       Impact factor: 9.139

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.